Mounjaro activates the actions of two natural substances in your body called Glucose-dependant insulinotropic polypeptides (GIP) and Glucagon l-like peptide-1 (GLP-1). Munjaro primarily works by regulating your appetite giving you sense of satiety (fullness). Making you feel less hungry and experience less cravings.
By mimicking the effect of both naturally occuring hormones, Mounjaro has been shown to have greater weight loss potential than medicines that work on GLP-1 alone.
Weight loss results are promising, with clinical trials showing that at 72 weeks of consistent Tirzepatide use, the average weight loss was 22.5%.
Various doses of Wegovy and Mounjaro are available with patients starting on a lower dose and gradually increasing each month as needed.
Mounjaro is available for patients with a body mass index (BMI) of 30 or over. Or a BMI of 27 and over where additional health conditions relaced to body weight such as high blood pressure are present.
If you are interested to find out more about medical weight loss management and see if you meet the criteria please make an initial enquiry with our team of health care professions by clicking below to complete our online assessment form.
We will contact you shortly to confirm your eligibility and if suitable to arrange an appointment.